Key facts
- Simergent’s last known valuation is $21.3M (Apr 2019).
- It has raised $27.4M across 1 recorded rounds; the latest was Early Stage VC ($8.8M) in Mar 2024.
- Notable investors include National Institutes of Health, Matter (Consulting Services (B2B)), Angel Physicians Fund, MTT Ventures, National Institute of Diabetes and Digestive and Kidney Diseases — 8 tracked in total.
- Simergent has filed 2 Form Ds with the SEC since 2024, most recently Mar 2026 ($8.8M sold to 57 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Simergent
Funding rounds
1 roundsAbout Simergent
Developer of an automated peritoneal dialysis device designed to create affordable home dialysis for emerging markets. The company's device is cost-effective, easy to use, and includes a disposable tubing set that troubleshoots independently, enabling patients to live a normal life and socialize with family and friends even while receiving treatment on a home dialysis system.
- Sector
- Healthcare
- HQ
- Oklahoma City, OK, United States
- Founded
- 2014
- Employees
- 8
- Website
- simergent.com/
- Ownership
- Privately Held (backing)
Simergent doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Simergent shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Simergent in its N-PORT filings yet. We sweep new filings monthly.